GSK Advances Toward Functional Cure for Chronic Hepatitis B with Bepirovirsen
New clinical data suggest bepirovirsen could offer a finite treatment alternative to lifelong antivirals for chronic hepatitis B infection. Achieving functional cure after six months marks a potential paradigm shift in this infectious disease area.
Key Developments
- GSK’s bepirovirsen met primary goals in two Phase 3 studies targeting chronic hepatitis B.
- The therapy achieved functional cure rates after six months of treatment.
- This antisense oligonucleotide approach could replace long-term antiviral therapies that patients currently must take indefinitely.
Implications
- Functional cure represents a significant clinical milestone, potentially reducing the disease burden and improving patient outcomes.
- This advancement positions GSK competitively within liver infectious disease therapeutics.
Context
Chronic hepatitis B affects millions worldwide, and current treatments mainly suppress viral replication without cure. A finite, functionally curative therapy could transform patient management and global health impact.
Source: medcitynews.com
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.